Nisha Joseph
Overview
Nisha Joseph, MD is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Joseph was named the first H. Jean Khoury Fellow in Leukemia and Bone Marrow Transplant. A hematologist, she specializes in the treatment of multiple myeloma and plasma cell disorders with expertise in stem cell transplantation and cellular therapies.
Dr. Joseph holds professional memberships with American Society of Clinical Oncology and American Society of Hematology.
Academic Appointment
- Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from Ohio State University
Research
Publications
-
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma.
Blood Adv Volume: 9 Page(s): 2438 - 2442
05/27/2025 Authors: Potdar SV; Kapadia S; Azeem MI; Radzievski R; Lakhani K; Joseph NS; Kaufman JL; Hofmeister CC; Gupta VA; Lonial S -
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes.
Clin Lymphoma Myeloma Leuk
04/11/2025 Authors: Varga C; Robinson M; Gupta V; Hofmeister CC; Nooka AK; Kaufman JL; Dhodapkar MV; Lonial S; Borden S; Ferreri C -
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract.
Clin Lymphoma Myeloma Leuk
04/08/2025 Authors: Scott SA; Roberts DL; Gupta VA; Joseph NS; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK; Kaufman JL -
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.
NPJ Vaccines Volume: 9 Page(s): 201
10/27/2024 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC -
How to rescue a DreaMM deferred .
Med Volume: 5 Page(s): 1048 - 1049
09/13/2024 Authors: Joseph NS; Lonial S -
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
Blood Cancer J Volume: 14 Page(s): 159
09/13/2024 Authors: Joseph NS; Kaufman JL; Gupta VA; Hofmeister CC; Dhodapkar MV; Boise LH; DiCamillo SM; Roberts D; Nooka AK; Lonial S -
Optimizing autologous stem cell collections for patients with multiple myeloma receiving G-CSF and Plerixafor: A single center project.
J Clin Apher Volume: 39 Page(s): e22127
06/01/2024 Authors: Javanbakht A; Stringer S; Anderson H; Hamilton E; Philip A; Waller EK; Langston AA; Joseph N; Roback JD; Schneider T -
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.
Blood Cancer J Volume: 13 Page(s): 191
12/20/2023 Authors: Scott SA; Marin EM; Maples KT; Joseph NS; Hofmeister CC; Gupta VA; Dhodapkar MV; Kaufman JL; Lonial S; Nooka AK -
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.
Res Sq
09/21/2023 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC -
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
JCO Oncol Pract Volume: 19 Page(s): 793 - 798
09/01/2023 Authors: Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK